T. Hirashima

1.8k total citations
54 papers, 1.2k citations indexed

About

T. Hirashima is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, T. Hirashima has authored 54 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Oncology, 33 papers in Pulmonary and Respiratory Medicine and 23 papers in Molecular Biology. Recurrent topics in T. Hirashima's work include Lung Cancer Treatments and Mutations (27 papers), Lung Cancer Research Studies (21 papers) and Cancer therapeutics and mechanisms (11 papers). T. Hirashima is often cited by papers focused on Lung Cancer Treatments and Mutations (27 papers), Lung Cancer Research Studies (21 papers) and Cancer therapeutics and mechanisms (11 papers). T. Hirashima collaborates with scholars based in Japan, United States and United Kingdom. T. Hirashima's co-authors include Kazuhiko Nakagawa, M. Fukuoka, Satoshi Kudoh, N Masuda, Ichiro Kawase, Takashi Yana, Takefumi Komiya, Y Kusunoki, Kunihiko Matsui and Takashi Nitta and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

T. Hirashima

50 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
T. Hirashima Japan	19	896	660	564	152	124	54	1.2k
Hiroaki Ozasa Japan	17	730 0.8×	479 0.7×	437 0.8×	69 0.5×	167 1.3×	80	1.1k
Fabrice Branle Switzerland	15	951 1.1×	796 1.2×	578 1.0×	219 1.4×	209 1.7×	36	1.5k
A-P Meert Belgium	7	732 0.8×	799 1.2×	548 1.0×	55 0.4×	266 2.1×	17	1.3k
D. Gandara United States	11	377 0.4×	203 0.3×	478 0.8×	97 0.6×	83 0.7×	26	837
M. Fukuoka Japan	16	1.1k 1.2×	570 0.9×	787 1.4×	334 2.2×	72 0.6×	62	1.4k
Kalliopi Andrikou Italy	16	534 0.6×	287 0.4×	189 0.3×	101 0.7×	223 1.8×	54	837
N. Saijo Japan	16	520 0.6×	438 0.7×	332 0.6×	76 0.5×	73 0.6×	62	980
Apar Pataer United States	18	715 0.8×	876 1.3×	293 0.5×	45 0.3×	178 1.4×	32	1.4k
Gonzalo Recondo United States	15	637 0.7×	576 0.9×	386 0.7×	66 0.4×	313 2.5×	54	1.1k
Satoshi Yuki Japan	19	819 0.9×	435 0.7×	201 0.4×	52 0.3×	189 1.5×	129	1.1k

Countries citing papers authored by T. Hirashima

Since Specialization

Citations

This map shows the geographic impact of T. Hirashima's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by T. Hirashima with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites T. Hirashima more than expected).

Fields of papers citing papers by T. Hirashima

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by T. Hirashima. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by T. Hirashima. The network helps show where T. Hirashima may publish in the future.

Co-authorship network of co-authors of T. Hirashima

This figure shows the co-authorship network connecting the top 25 collaborators of T. Hirashima. A scholar is included among the top collaborators of T. Hirashima based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with T. Hirashima. T. Hirashima is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hirashima, T., Kiyotaka Yoh, Hideo Saka, et al.. (2020). 387P Phase Ib study of savolitinib ± osimertinib in Japanese patients (pts) with advanced solid malignancies & EGFRm NSCLC: TATTON part C. Annals of Oncology. 31. S1393–S1393. 1 indexed citations

Shinden, Yoshiaki, T. Hirashima, Nijiro Nohata, et al.. (2020). Molecular pathogenesis of breast cancer: impact of miR-99a-5p and miR-99a-3p regulation on oncogenic genes. Journal of Human Genetics. 66(5). 519–534. 24 indexed citations

Nakajo, Akihiro, et al.. (2020). The usefulness and utilization of a detachable steel wire-rimmed retractor (KN retractor) for endoscopic thyroid and parathyroid surgery. Surgery Today. 51(1). 159–164. 1 indexed citations

Kimura, Masashi, Kazumi Nishino, Yukihiro Yano, et al.. (2019). P2.16-19 Real World Data in Non-Small Cell Lung Cancer with Activating EGFR Mutation - A Multicenter Observational Study. Journal of Thoracic Oncology. 14(10). S872–S873.

Nakajo, Akihiro, Koji Minami, Yoshiaki Shinden, et al.. (2019). Upgraded bidirectional approach video-assisted neck surgery (BAVANS) using a rigid endoscope with variable viewing direction for advanced endoscopic lymph node dissection in thyroid cancer patients. Surgery Today. 50(7). 778–782. 2 indexed citations

Yoshioka, Hiroshige, Mototsugu Shimokawa, Takashi Seto, et al.. (2019). Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer. Annals of Oncology. 30(12). 1978–1984. 68 indexed citations

Taniguchi, Yoshihiko, Akihiro Tamiya, Kenji Nakahama, et al.. (2019). P1.01-77 Impact of Oral Drugs on the Prognosis of Non-Small-Cell Lung Cancer Patients Treated with Nivolumab. Journal of Thoracic Oncology. 14(10). S390–S390. 3 indexed citations

Taniguchi, Yoshihiko, Akihiro Tamiya, Kenji Nakahama, et al.. (2017). Predictive factors for poor progression-free survival in patients with non-small-cell lung cancer treated with nivolumab. Annals of Oncology. 28. v412–v413. 36 indexed citations

Tamiya, Akihiro, Motohiro Tamiya, Takashi Nishihara, et al.. (2016). Afatinib efficacy and cerebrospinal fluid concentration in NSCLC patients with EGFR mutation developing leptomeningeal carcinomatosis. Annals of Oncology. 27. vi428–vi428. 6 indexed citations

10.

Yoshioka, Hiroshige, K. Azuma, Nobuyuki Yamamoto, et al.. (2015). A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study). Annals of Oncology. 26(10). 2066–2072. 89 indexed citations

11.

Yamamoto, Nobuyuki, Haruyasu Murakami, Hidetoshi Hayashi, et al.. (2013). CYP2C19 genotype-based phase I studies of a c-Met inhibitor tivantinib in combination with erlotinib, in advanced/metastatic non-small cell lung cancer. British Journal of Cancer. 109(11). 2803–2809. 18 indexed citations

12.

Yamamoto, Nobuyuki, Haruyasu Murakami, Tomohiro Nishina, et al.. (2013). The effect of CYP2C19 polymorphism on the safety, tolerability, and pharmacokinetics of tivantinib (ARQ 197): results from a phase I trial in advanced solid tumors. Annals of Oncology. 24(6). 1653–1659. 28 indexed citations

13.

Tamiya, Akihiro, Motohiro Tamiya, Takayuki Shiroyama, et al.. (2012). Dose escalation study of carboplatin–pemetrexed followed by maintenance pemetrexed for elderly patients with advanced nonsquamous nonsmall-cell lung cancer. Annals of Oncology. 24(4). 980–985. 22 indexed citations

14.

Matsui, K, N Masuda, M. Fukuoka, et al.. (1998). Phase II trial of carboplatin plus oral etoposide for elderly patients with small-cell lung cancer. British Journal of Cancer. 77(11). 1961–1965. 39 indexed citations

15.

Masuda, N, K Matsui, Nobuhide Takifuji, et al.. (1998). Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer.. Journal of Clinical Oncology. 16(10). 3329–3334. 87 indexed citations

16.

Miyamoto, Keisuke, Takuro Wada, Yasunobu Kanamori, et al.. (1996). [Trial of home infusion therapy for near-terminal stage patients with lung cancer].. PubMed. 23 Suppl 3. 305–10.

17.

Kubo, Akihito, T. Hirashima, Nobuhisa Masuda, et al.. (1996). Point mutations of the topoisomerase IIalpha gene in patients with small cell lung cancer treated with etoposide.. PubMed. 56(6). 1232–6. 32 indexed citations

18.

Takahashi, Takashi, et al.. (1995). Risk Factors of Operative Death and Prognosis Following Operations for Esophageal Cancer in the Elderly.. Nippon Ronen Igakkai Zasshi Japanese Journal of Geriatrics. 32(12). 781–785.

19.

Masuda, N, M. Fukuoka, Satoshi Kudoh, et al.. (1994). Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer.. Journal of Clinical Oncology. 12(1). 90–96. 78 indexed citations

20.

Masuda, N, M. Fukuoka, S. Kudoh, et al.. (1993). Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer. British Journal of Cancer. 68(4). 777–782. 85 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact